224 related articles for article (PubMed ID: 33514790)
21. QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®.
Jaffar-Aghaei M; Khanipour F; Maghsoudi A; Sarvestani R; Mohammadian M; Maleki M; Havasi F; Rahmani H; Karagah AH; Kazemali MR
Eur J Pharm Sci; 2022 Jun; 173():106171. PubMed ID: 35378209
[TBL] [Abstract][Full Text] [Related]
22. Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study.
Joshi S; Rathore AS
BioDrugs; 2020 Apr; 34(2):209-223. PubMed ID: 31975160
[TBL] [Abstract][Full Text] [Related]
23. Characterization of asparagine 330 deamidation in an Fc-fragment of IgG1 using cation exchange chromatography and peptide mapping.
Zhang YT; Hu J; Pace AL; Wong R; Wang YJ; Kao YH
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Aug; 965():65-71. PubMed ID: 24999246
[TBL] [Abstract][Full Text] [Related]
24. Charge heterogeneity: Basic antibody charge variants with increased binding to Fc receptors.
Hintersteiner B; Lingg N; Zhang P; Woen S; Hoi KM; Stranner S; Wiederkum S; Mutschlechner O; Schuster M; Loibner H; Jungbauer A
MAbs; 2016; 8(8):1548-1560. PubMed ID: 27559765
[TBL] [Abstract][Full Text] [Related]
25. Charge variant analysis of proposed biosimilar to Trastuzumab.
Dakshinamurthy P; Mukunda P; Prasad Kodaganti B; Shenoy BR; Natarajan B; Maliwalave A; Halan V; Murugesan S; Maity S
Biologicals; 2017 Mar; 46():46-56. PubMed ID: 28087106
[TBL] [Abstract][Full Text] [Related]
26. Multifaceted assessment of rituximab biosimilarity: The impact of glycan microheterogeneity on Fc function.
Kang J; Kim SY; Vallejo D; Hageman TS; White DR; Benet A; Coghlan J; Sen KI; Ford M; Saveliev S; Tolbert TJ; Weis DD; Schwendeman SP; Ruotolo BT; Schwendeman A
Eur J Pharm Biopharm; 2020 Jan; 146():111-124. PubMed ID: 31841688
[TBL] [Abstract][Full Text] [Related]
27. Characterization of recombinant monoclonal antibody charge variants using WCX chromatography, icIEF and LC-MS/MS.
Liu H; Ren W; Zong L; Zhang J; Wang Y
Anal Biochem; 2019 Jan; 564-565():1-12. PubMed ID: 30291836
[TBL] [Abstract][Full Text] [Related]
28. Highly purified charge variants of a proposed biosimilar to Omalizumab: impact on in vitro potency and stability under thermal stress.
Gupta T; Seshadri S
Bioprocess Biosyst Eng; 2024 Jan; 47(1):57-64. PubMed ID: 38156991
[TBL] [Abstract][Full Text] [Related]
29. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
[TBL] [Abstract][Full Text] [Related]
30. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
Cerutti ML; Pesce A; Bès C; Seigelchifer M
BioDrugs; 2019 Jun; 33(3):307-319. PubMed ID: 30927214
[TBL] [Abstract][Full Text] [Related]
31. Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev
Weiser S; Burns C; Zartler ER
J Oncol Pharm Pract; 2023 Jul; 29(5):1032-1043. PubMed ID: 35312402
[TBL] [Abstract][Full Text] [Related]
32. Titer and charge-based heterogeneity multiattribute monitoring of mAbs in cell culture harvest using 2D ProA CEX MS.
Sarin D; Kumar S; Rathore AS
Talanta; 2024 Aug; 276():126232. PubMed ID: 38749159
[TBL] [Abstract][Full Text] [Related]
33. Charge variants characterization of a monoclonal antibody by ion exchange chromatography coupled on-line to native mass spectrometry: Case study after a long-term storage at +5°C.
Leblanc Y; Ramon C; Bihoreau N; Chevreux G
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Mar; 1048():130-139. PubMed ID: 28242492
[TBL] [Abstract][Full Text] [Related]
34. Cation exchange chromatography on a monodisperse 3 µm particle enables extensive analytical similarity assessment of biosimilars.
Füssl F; Millán-Martín S; Bones J; Carillo S
J Pharm Biomed Anal; 2023 Sep; 234():115534. PubMed ID: 37343453
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the acidic species of a monoclonal antibody using weak cation exchange chromatography and LC-MS.
Ponniah G; Kita A; Nowak C; Neill A; Kori Y; Rajendran S; Liu H
Anal Chem; 2015 Sep; 87(17):9084-92. PubMed ID: 26222016
[TBL] [Abstract][Full Text] [Related]
36. Characterization of alanine to valine sequence variants in the Fc region of nivolumab biosimilar produced in Chinese hamster ovary cells.
Li Y; Fu T; Liu T; Guo H; Guo Q; Xu J; Zhang D; Qian W; Dai J; Li B; Guo Y; Hou S; Wang H
MAbs; 2016 Jul; 8(5):951-60. PubMed ID: 27050807
[TBL] [Abstract][Full Text] [Related]
37. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.
Chen L; Wang L; Shion H; Yu C; Yu YQ; Zhu L; Li M; Chen W; Gao K
MAbs; 2016 Oct; 8(7):1210-1223. PubMed ID: 27380163
[TBL] [Abstract][Full Text] [Related]
38. Tracking the Behavior of Monoclonal Antibody Product Quality Attributes Using a Multi-Attribute Method Workflow.
Jakes C; Millán-Martín S; Carillo S; Scheffler K; Zaborowska I; Bones J
J Am Soc Mass Spectrom; 2021 Aug; 32(8):1998-2012. PubMed ID: 33513021
[TBL] [Abstract][Full Text] [Related]
39. A comprehensive approach for evaluating charge heterogeneity in biosimilars.
Xiao Z; Yin X; Han L; Sun B; Shen Z; Liu W; Yu F
Eur J Pharm Sci; 2018 Mar; 115():19-24. PubMed ID: 29325754
[TBL] [Abstract][Full Text] [Related]
40. Hyphenation of strong cation exchange chromatography to native mass spectrometry for high throughput online characterization of charge heterogeneity of therapeutic monoclonal antibodies.
Ma F; Raoufi F; Bailly MA; Fayadat-Dilman L; Tomazela D
MAbs; 2020; 12(1):1763762. PubMed ID: 32370592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
